Oncological safety of reconstruction with autologous fat grafting in breast cancer patients: a systematic review and meta-analysis

• Published in: International journal of clinical oncology 2022-09, Vol.27 (9), p.1379-1385
• Main Authors: Sun, Jiale, Liang, He, Lin, Dongcai, Han, Bing, Zhang, Tiran, Gao, Jidong
• Format: Article
• Language: English
• Subjects: Autografts; Breast cancer; Cancer Research; Medicine; Medicine & Public Health; Meta-analysis; Oncology; Reconstructive surgery; Review Article; Surgical Oncology; Survival
• ISSN: 1341-9625; 1437-7772
• DOI: 10.1007/s10147-022-02207-8

To evaluate the oncological safety of autologous fat grafting and its effect on disease-free survival and local recurrence in breast cancer patients with autologous fat grafting (AFG) reconstruction. A literature search was performed using the Pubmed, Medline, Web of Science, and Cochrane libraries from January 2011 to March 2020, in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, to identify all relevant studies involving the application of autologous fat grafting in breast cancer reconstruction procedures. The primary outcome of the meta-analysis was a difference in incidence rates of locoregional recurrence and disease-free survival (DFS) between patients who had autologous fat grafting and controls. A total of 11 studies were included. Eight studies reported local–regional recurrences (LRR) and five studies reported disease-free survival (DFS) in 5,886 patients. Our meta-analysis of all included studies about survival outcomes showed AFG was not associated with increased LRR and DFS. Pooled hazard ratios (HRs) (95% CIs) for LRR and DFS were 1.26 (0.90–1.76) and 1.27 (0.96–1.69), respectively. According to the published literature, autologous fat grafting did not result in an increased rate of LRR and DFS in patients with breast cancer. Autologous fat grafting can, therefore, be performed safely in breast reconstruction after breast cancer.